Erratum: Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma [Diseases of the Esophagus (2012) ]doi: 10.1111/j.1442-2050.2012.01332.x;Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma

Diseases of the Esophagus

Volumn 26, Issue 5, 2013, Pages 487-495

  Guo, X F ^a   Zhu, X F ^a   Zhong, G S ^b   Deng, B G ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b First Affiliated Hospital of Xinxiang Medical University   (China)

Author keywords

Cisplatin; EGFR; Esophageal cancer; HER2; Lapatinib

Indexed keywords

ACTIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ESOPHAGUS CARCINOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84880324655     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12018     Document Type: Erratum

References (33)

1. Homs M Y, Voest E E, Siersema P D. Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs 2009; 14: 329-39.
2. Mimura K, Kono K, Maruyama T etal. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody dependent cellular cytotoxicity (ADCC) of EGFR and HER2 over-expressing esophageal cancer cell line. Int J Cancer 2011; 129: 2408-16.
3. Cunningham D, Allum W H, Stenning S P etal. Perioprative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
4. Tepper J, Krasna M J, Niedzwiecki D etal. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-92.
5. Ku G Y, Ilson D H. Esophagogastric cancer: targeted agents. Cancer Treat Rev 2010; 36: 235-48.
6. Holbro T, Civenni G, Hynes N E. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110.
7. Itakura Y, Sasano H, Shiga C etal. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994; 74: 795-804.
8. Gibault L, Metges J P, Conan-Charlet V etal. Diffuse EGFR staining is associated with reduced overall survival in locally advanced esophageal squamous cell cancer. Br J Cancer 2005; 93: 107-15.
9. Graus-Porta D, Beerli R R, Daly J M, Hynes N E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-55.
10. Safran H, Dipetrillo T, Akerman P etal. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 67: 405-9.
11. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 2010; 36: S11-15.
12. Bang Y J, Van Cutsem E, Feyereislova A etal. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010; 376: 687-97.
13. Ross J S, McKenna B J. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19: 554-68.
14. Kawaguchi Y, Kona K, Mimura K etal. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in esophageal squamous cell carcinoma. Br J Cancer 2007; 97: 494-501.
15. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007; 43: 481-9.
16. Xia W, Mullin R J, Keith B R etal. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-63.
17. Geyer C E, Forster J, Lindquist D etal. Lapatinib plus cepecitabine for HER2-posivite advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
18. Johnston S, Trudeau M, Kaufman B etal. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008; 26: 1066-72.
19. Iqbal S, Goldman B, Fenoglio-Preiser C M etal. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011; 22: 2610-5.
20. Hecht J, Urba S, Koehler M etal. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses (Abstract). Proc GI ASCO 2008; 43.
21. Guo X F, Zhu X F, Shang Y, Zhang S H, Zhen Y S. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 show potent antitumor activity. Clin Cancer Res 2010; 16: 2085-94.
22. Chou T C, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1993; 4: 450-54.
23. Tkaczuk K H. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 2009; 31: 2273-89.
24. Yarden Y, Sliwkowski M X. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
25. Wei Q C, Chen L R, Sheng L M, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumors and corresponding metastases. Int J Oncol 2007; 31: 493-9.
26. Tew W P, Kelsen D P, Ilson D H. Targeted therapies for metastatic esophageal cancer. Oncologist 2005; 10: 590-601.
27. Rusnak D W, Lackey K, Affleck K etal. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
28. Coley H M, Shotton C F, Ajose-Adeogun A, Modjtahedi H, Thomas H. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol 2006; 72: 941-8.
29. Kondo N, Tsukuda M, Ishiguro Y etal. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2010; 23: 957-63.
30. MuHugh L A, Sayan A E, Mejlvang J etal. Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol 2009; 34: 1156-63.
31. Tanizaki J, Okamoto I, Takezawa K etal. Synergistic antitumor effects of S-1 and HER-2 targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 2010; 9: 1198-207.
32. Rusnak D W, Alligood K J, Mullin R J etal. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumor cell lines. Cell Prolif 2007; 40: 580-94.
33. Havaleshko D M, Smith S C, Cho H etal. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia 2009; 11: 1185-93.